Patient Recruitment Applications & Studies

81. Clinical Trial Recovery - Rescued Cohorts 10/12/2021

    A large pharma Sponsor approached QPS to jump into a trial early and complete initial phases of recruitment and enrollment into a large, multi-cohort clinical trial. This case study outlines the challenges faced and the solutions put in place to deliver the study successfully.

82. Datavant Life Sciences Case Study: Finding Rare Disease Patients 9/23/2021

    Hereditary ATTR amyloidosis is a rare disease that affects 50,000 patients world-wide, shortening patient life expectancy to between five and thirteen years.1 Read how Datavant tracked down these patients.

83. Leading Sponsor Delivers Enrollment 24 Months Ahead Of Schedule 9/20/2021

    Read the available case study to see how a leading sponsor delivers enrollment twenty four months ahead of schedule.

84. Overcoming Trial Recruitment Challenges In NASH Using De-Identified Patient Linking 8/25/2021

    Recruiting patients for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials can be a challenge. Read on to see how this challenge was overcome.

85. Study Start-Up And Enrollment 7/27/2021

    IQVIA Biotech was approached by a clinical-stage biopharmaceutical company to run its Phase II prostate cancer drug trial in the U.S. For more information, download the available case study.

86. Achieving Recruitment Objectives In Dermatology Trial: Reducing Timeline And Cost 7/26/2021

    IQVIA Biotech was selected to help a U.S. biopharmaceutical company examine the safety and efficacy of its investigational therapy for the treatment of moderate-to-severe hidradenitis suppurativa (HS), a chronic skin condition that causes small, but painful lumps under the skin. This case study will highlight IQVIA Biotech’s unique strategies for site selection and centralized recruitment approach to drive enrollment.

87. Quality Trial Study Design For Phase II For Primary Biliary Cholangitis Improves Enrollment 7/12/2021

    The only widely accepted treatment fro Primary biliary cholangitis (PBC) is Ursodeoxycholic Acid (UDCA), which can delay disease progression and improve long-term survival but does not address the underlying disease. A solution provider drew on their expertise to contribute to the study design and selection of appropriate endpoints for a Phase II trial with a European Pharmaceutical company. Operational teams were then able to focus on data capture and cleaning, leading to safety review assessments, as well as a key Interim analysis, final analysis and clinical study report – all delivered on budget and within required timelines.

88. Global Pharma Saves 4 Months Recruitment Efforts With Digital Campaigning 7/1/2021

    A large global pharma initiated a phase III study testing the efficacy of combining two existing drugs in overactive bladder patients. The study planned to enroll 3,500 patients worldwide a 10-month period across and included sites in multiple countries in the Nordic region. Read how engaging Trialbee from study start to ensured enrollment deadlines were met as planned.

89. Ulcerative Colitis Study Gets Back On Track With Recruitment Support In Four Countries 6/30/2021

    A global biotech initiated a phase IIb orphan drug study for the treatment of chronic ulcerative colitis. After deploying traditional recruitment methods, the sponsor met only 60% of its patient enrollment target, and extended the recruitment window an additional six months. Finding the right partner allowed them to successfully close the enrollment gap and move the study forward as planned.

90. Retention And Compliance In A Multicenter, Open-Label Clinical Trial 6/18/2021

    Missing outcome data caused by patient dropout and poor compliance not only jeopardize the scientific validity of a study, but also come at a significant financial cost to study sponsors. Technology and behavioral science offer potential solutions that together can address these challenges through patient-centric design of tools. This case study examines retention and compliance in a multicenter, open-label clinical trial (N=36) with the use of the Linkt mobile application.